Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01007552 · ClinicalTrials.gov registry record · Phase 2
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01007552 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 50 participants.
The verdict
NCT01007552, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To assess the proposed therapy for patients with advanced gallbladder or biliary cancers.
Interventions
- DRUG Gemcitabine, Capecitabine and Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01007552
The ClinicalTrials.gov registry entry for NCT01007552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Capecitabine and Bevacizumab is the first listed.
NCT01007552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01007552 about?
NCT01007552 is a clinical study titled "A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts". To assess the proposed therapy for patients with advanced gallbladder or biliary cancers.
What is the current status of trial NCT01007552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-12. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01007552?
The interventions under investigation include: Gemcitabine, Capecitabine and Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01007552?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.